Effect of Xuebijing injection, somatostatin monotherapy and their combined therapy on inflammation and prognosis in acute severe acute pancreatitis
10.7619/jcmp.201809010
- VernacularTitle:血必净注射液、生长抑素单药及联合用药对急性重症胰腺炎的炎症改善及预后的影响
- Author:
Tianjing WANG
1
;
Xiuhua ZHOU
Author Information
1. 中国医科大学附属第四医院急诊科
- Keywords:
Xuebijing injection;
somatostatin;
combination therapy;
acute severe pancreatitis;
inflammation;
prognosis
- From:
Journal of Clinical Medicine in Practice
2018;22(9):39-42
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of Xuebijing injection,somatostatin monotherapy and their combination therapy on the improvement of inflammation and prognosis in acute severe pancreatitis.Methods A total of 90 patients with acute severe pancreatitis treated in our hospital were enrolled in this study.Patients were divided into group A,group B and group C,with 30 cases in each group.The patients in group A were treated with Xuebijing injection alone,and the patients in group B were treated with somatostatin alone,and patients in group C were treated with Xuebijing injection and somatostatin,and all the treatment was lasted for 7 days.The alleviation time of clinical symptoms,improvement of inflammation and prognosis in three groups before and after treatment were observed and compared.Results After treatment,the anal defecation recovery time,abdominal pain relief time,bowel sounds recovery time and abdominal distension time in the three groups were lower than treatment before,and group C were lower than group A and group B (P ＜ 0.05).The levels of interleukin-6 (IL-6),tumour necrosis factor-α (TNF-α) and C-reactive protein (CRP) were significantly lower in group C than those in group A and group B (P ＜0.05).The APACHE-Ⅱ scores after treatment was higher than treatment before,and C group was lower than A group,B group (P ＜0.05).Conclusion Xuebijing injection in combined with somatostatin for acute severe pancreatitis has significantly better efficacy than monotherapy,and it can improve the efficacy of inflammation treatment,and prognosis.
